Most TB-500 Claims Use the Larger Protein

No human trial has tested the sold fragment

Start with the missing test. Researchers haven’t finished a controlled human trial of TB-500. Animal studies supplied most repair findings. Those studies usually used the larger parent protein. The human safety test used that larger protein too.

TB-500 is a lab-made piece with seven protein parts. It copies parts 17 to 23 of thymosin beta-4. The full protein helps cells change shape and move. The seven-part copy may not act the same.

TB-500 has no approved use in people. It’s also banned in tested sports. When someone cites a human study, ask which form was tested. That answer changes what the study can prove for you.

The sold fragment is much smaller than the full protein

TB-500 copies parts 17-23 of thymosin beta-4. The full thymosin beta-4 protein has 43-amino-acid parts. Proteins are built from smaller parts called amino acids. Its lab weight is about 4963 daltons, a unit used to compare protein sizes. That figure shows why TB-500 is about one-fifth as large.

In the full protein, the copied part holds actin. Actin helps a cell keep its shape and move. Some lab sellers treat TB-500 and the full protein as one thing. They aren’t the same.

The sold fragment contains seven parts. Lab gene codes don’t help with your choice. The size gap matters when you weigh the claim. Human trials haven’t shown that the fragment copies the full protein.

The full protein helped cells move

Inside a cell, thymosin beta-4 holds actin. Actin helps give the cell its shape. Holding actin can change cell movement. That may matter after tissue is hurt.

An X-ray image showed one full protein holding one actin protein, a 1:1 pair ^[12]. The image showed their contact at 2 Å, a unit for a distance far smaller than a cell. That fine detail shows how the full protein holds actin. It doesn’t show whether the sold fragment heals you.

Other animal and cell work found less scar tissue. It also found new blood vessels and less cell death ^[10]. Platelets, the blood parts that help a clot form, release the full protein near harm. Almost none of this work tested TB-500 alone.

A middle amount helped rats more than the highest

A broad review, 2026. The review covered approved and unapproved peptides. It included work on the sold fragment and thymosin beta-4. Animal tests showed signs of tissue repair ^[8]. Human safety facts were scarce, so serious harm still couldn’t be ruled out.

A rat stroke study, 2014. Male rats received thymosin beta-4 after a blocked brain blood vessel. This wasn’t a test in people. The amounts were 2, 12, or 18 milligrams per kilogram. Treatment began 24 hours later and returned every 3 days for 4 more doses.

The rats improved at 2 and 12 milligrams per kilogram. The change lasted from day 14 through day 56 ^[9]. The 18 milligrams per kilogram amount didn’t help. A math model, not a rat group, placed its best estimate near 3.75 milligrams per kilogram. No rats received that exact amount.

More wasn’t better in this rat test. None of these amounts is a human dose. This full-protein study can’t tell you how the sold fragment acts.

A thymosin beta-4 repair review, 2012. This review covered the full protein. It found work on cell movement and stem cells ^[10]. Stem cells can grow into other kinds of cells. The review also found less scar tissue and more new blood vessels.

A Phase 1 human safety test, 2010. That Phase label means a small early test that mainly looks for immediate harm. It can’t show whether a drug heals an injury. The test had 40 healthy people. Four groups had 10 people each. They received thymosin beta-4 by vein for 14 days ^[11]. The amounts were 42, 140, 420, or 1260 milligrams.

Most bad effects were mild or fair. No serious harm was reported. Blood levels fell more slowly after larger amounts. Your body would take longer to remove the protein. The paper didn’t say that slower removal caused harm. This thymosin beta-4 test didn’t use TB-500.

An X-ray study, 2004. The lab used thymosin beta-4, actin, and a helper protein. The helper was marked 1 in the paper. The image showed one full protein holding one actin protein, a 1:1 pair. It showed their contact at 2 Å, a lab measure much smaller than a cell ^[12]. The study didn’t test the short fragment in you.

User stories don’t prove that a fragment heals

People using TB-500 for research often tell similar stories. The users gave these reports themselves. No controlled trial found or checked the changes. Those stories don’t establish that TB-500 caused anything.

What users reported: Some said tendon, ligament, or muscle pain eased sooner. Others said joints felt less stiff. Better movement and calmer soreness also came up. A few mentioned skin healing or more hair.

What users disliked: Redness, swelling, or pain near the shot came up most. Tiredness was also common. Some people named nausea, low mood, or feeling faint. A report alone can’t tell you what caused the change.

What the papers warn about:

• Human safety for TB-500 itself is nearly unknown. No finished controlled human trial has tested TB-500. A 2026 review found possible repair in animals and scant safety facts for people ^[8][11].
• The full protein raises a cancer concern. Some cancers carry too much of that protein. A tumor might also benefit from cells moving and blood vessels growing.
• TB-500 is banned in tested sport ^[8]. Sports labs can find TB-500 and pieces left when the body breaks it down.
• New muscle fibers didn’t bring more strength. Mice born with weak muscles grew more fibers. Their strength, heart work, and scars didn’t improve.
• Most hopeful tests used the full protein. TB-500 is only one small piece. Researchers haven’t proved that results from thymosin beta-4 also fit TB-500 ^[10].
• A research label can’t confirm the contents. The contents may not be pure or match the label. That adds another risk.
• Bleeding and clotting haven’t been tested in people. The full protein helps blood vessels form and comes from platelets near harm. That raises a concern around surgery.
• There are no safety facts for pregnancy, nursing, or young people. These groups weren’t studied. TB-500 may affect cell movement and blood vessel growth.

Check the full protein and sold fragment separately

TB-500 gets its cell movement claim from the parent protein. Yet the human safety test used that full protein ^[11]. Most animal repair work did too. You’ll find this gap behind many sales claims. TB-500 isn’t the full protein.

Wolverine keeps the TB-500 gap and adds another peptide. No controlled trial tested the pair. GHK-Cu has small human studies, but only for skin and hair. One peptide’s study can’t prove another peptide’s claim.

The comparison page puts each form beside its test. Check the exact name, the test subject, and the measured change. When those facts don’t match, show the paper to your doctor.